UK markets close in 1 hour 58 minutes

MaxCyte, Inc. (MXCT.L)

LSE - LSE Delayed price. Currency in GBp
Add to watchlist
673.98-26.02 (-3.72%)
As of 01:47PM GMT. Market open.
Sign in to post a message.
  • S
    Santosh J
    The earnings were terrific. Way above expectations and estimates. What gives on price?
  • R
    RV
    Is CASDIN adding more or ARK starting a position- just wondering- I may be wrong on both counts.
  • O
    Offer
    I guess we found our bottom. Today could be big. I am assuming CRSP 110 is using MXCT.
  • Y
    Yahoo Finance Insights
    MaxCyte is down 10.38% to 9.50
  • O
    Offer
    I assume the news is because of of the Allogene news. They just received a hold on their trial. Looking at MaxCyte investor presentation ALLO is one of their customers. Since ALLO is using MaxCyte for their cell creation it is a double problem
    1) Fear of the unknown. maybe the problem found in the subject has nothing to do with the trial at all but potentially it could be derived by the MaxCyte Cell proccessing.
    2) Even if it is Allo fault AND had nothing to do with MaxCyte, the MaxCyte business model (Which is a great business model) relies on milestones such as phase completion and single digit from the drug revenue. No drug means no revenue.
    I think it is exactly why you should BUY MaxCyte. No matter who the winners and the losers will be, they will use MaxCyte. We never really expected all of the cell theraphy companies to be winners.
  • O
    Offer
    $SANA just signed a license agreement with $BEAM. Should be good for $MXCT as $SANA just recently signed an agreement with MaxCyte for the cells electroporation
  • R
    RV
    CASDIN adds:
    MXCT HEALTH CARE 13,971,334 $170,590,000 4.25 7 13,971,334 New 13.9083% Q3 2021 12.21 12.21 12.79 13F 2021-09-30 2021-11-15
  • S
    Santosh J
    Folks. Is the price dump a combo of larger market forces AND the fact that all the insiders in the c-suite sold a bunch of their stake in the past 3 weeks?!? Why the Armageddon?
  • Y
    Yahoo Finance Insights
    MaxCyte is down 9.46% to 11.58
  • Y
    Yahoo Finance Insights
    MaxCyte reached an all time low at 9.35
  • Y
    Yahoo Finance Insights
    MaxCyte is up 8.60% to 11.62
  • Y
    Yahoo Finance Insights
    MaxCyte reached an all time low at 8.90
  • Y
    Yahoo Finance Insights
    MaxCyte is up 7.25% to 11.76
  • Y
    Yahoo Finance Insights
    MaxCyte is up 7.11% to 11.00
  • D
    Dan
    Maybe nervous about J Stark Thompson leaving as chairman but he’s 78 and just semi-retiring I suspect. Not a reflection of MaxCyte potential. If I had any more cash I’d buy more now
  • R
    RV
    Okapi
    @OkapiCapital
    $MXCT with a solid Q2 beating analyst sales estimates by 15%.

    Q2 accelerated to 38% YY and would have been closer to 60% if not for a decline in lumpy program milestones that should accelerate over the coming quarters as partner programs mature.

    Guide looks very conservative.
    4:39 PM · Sep 13, 2021·Twitter for iPhone
  • O
    Offer
    I guess it's just one of the IPOs (Like most) that goes first down to the original IPO price before they take off.
    MXCT was valued in the UK I think about 750M so we are not far. Time to accumulate and then we fly.
    MXCT receives milestone payments based on progress in phases of trials on top of the single-digit from drug revenue so in the next few years we should see explosive growth with all the gene-editing companies working on Cell therapies. GLTA
  • Y
    Yahoo Finance Insights
    MaxCyte is down 8.43% to 10.10
  • S
    Santosh J
    Does anyone know what's happening with $MXCT today? Why the 5% drop on 10/25??
  • S
    Soon-Young
    What is going on?